Premium
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmi... Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The company's product, Phexxi (lactic acid, citric acid and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The company is also evaluating its investigational drug candidate EVO100 vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection (chlamydia) and Neisseria gonorrhoeae infection (gonorrhea) in women. Show more
Evofem Biosciences Announces Strong Preliminary Results for the First Quarter of 2023 PR Newswire SAN DIEGO, June 1, 2023 Increased net product revenue more than 35% in the first quarter of 2023...
Evofem Biosciences Announces 1-for-125 Reverse Stock Split PR Newswire SAN DIEGO, May 17, 2023 -- CUSIP number for Evofem will change to 30048L302 on May 18, 2023 -- -- Ticker symbol will change...
Evofem Wins Phexxi Coverage with Largest Payer in New York with No Prior Authorization Required PR Newswire SAN DIEGO, April 12, 2023 — Improves Phexxi coverage for more than 5.8 million New York...
Evofem Biosciences Announces Cost Reduction Measures PR Newswire SAN DIEGO, March 21, 2023 – Company cuts management pay and lowers headcount to decrease operating costs – – Reductions align with...
Evofem Biosciences Appoints Interim Chief Financial Officer PR Newswire SAN DIEGO, March 9, 2023 SAN DIEGO, March 9, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) is pleased to...
Evofem's Phexxi Contraceptive Gel Added to SimpleHealth Product Offering PR Newswire SAN DIEGO, Feb. 28, 2023 -- Phexxi is the first and only hormone-free contraceptive offered by reproductive...
Evofem Biosciences Announces FDA Orange Book Listing of Two Additional U.S. Patents for Phexxi PR Newswire SAN DIEGO, Feb. 27, 2023 -- Evofem now has four Orange Book listed patents covering...
Evofem Biosciences to Explore Strategic Alternatives to Maximize Shareholder Value PR Newswire SAN DIEGO, Feb. 23, 2023 SAN DIEGO, Feb. 23, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:...
Costco Adds Phexxi® to Member Prescription Program PR Newswire SAN DIEGO, Jan. 10, 2023 SAN DIEGO, Jan. 10, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that...
Multiple New Insurance Wins Expand and Improve Access to Phexxi® for Millions of Women PR Newswire SAN DIEGO, Jan. 9, 2023 -- Medicaid improves Phexxi coverage for more than 3.7 million lives...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
